Mohamed Sherif Salem/LinkedIn
Nov 9, 2025, 11:35
Mohamed Sherif Salem: Anti-Xa Monitoring Did Not Reduce Bleeding or Thromboembolic Events
Mohamed Sherif Salem, Senior Clinical Pharmacist at Andalusia Health Egypt, shared on LinkedIn:
”A 2025 systematic review found that routine anti-factor Xa (anti-Xa) monitoring during therapeutic LMWH therapy led to more dose changes but did not reduce bleeding or thromboembolic events.
Study details:
- Design: Systematic review (4 randomized trials + 44 observational studies; total 48 studies).
- Key dataset: 30 studies ( >3,000 patients) evaluated the relationship between measured anti-Xa activity and bleeding risk.
Findings
- Anti-Xa measurements prompted dose adjustments more frequently than no monitoring.
- There was no reduction in clinical end points (major bleeding or thromboembolism) in monitored versus unmonitored groups.
- Correlation between anti-Xa levels and bleeding (or thrombotic) outcomes was weak or absent in most studies.
Interpretation / practical implications:
- Routine anti-Xa monitoring for patients on therapeutic LMWH cannot be recommended based on current evidence. The data support continuing fixed or weight-based dosing in typical patients.
- Monitoring should be selective: consider anti-Xa measurement in patients where LMWH pharmacokinetics are likely unreliable (examples: significant renal impairment, extremes of body weight, ongoing active bleeding or when clinical management would change based on the result).”
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C.C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand
Read the full article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:34Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis